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Abstract
Background: Malignant mesothelioma (MM) is a rare, highly aggressive tumor, associated to asbestos exposure. To date no
chemotherapy regimen for MM has proven to be definitively curative, and new therapies for MM treatment need to be
developed. We have previously shown in vivo that piroxicam/cisplatin combined treatment in MM, specifically acts on cell
cycle regulation triggering apoptosis, with survival increase.
Methodology/Principal Findings: We analyzed, at molecular level, the apoptotic increase caused by piroxicam/cisplatin
treatment in MM cell lines. By means of genome wide analyses, we analyzed transcriptional gene deregulation both after
the single piroxicam or cisplatin and the combined treatment. Here we show that apoptotic increase following combined
treatment is mediated by p21, since apoptotic increase in piroxicam/cisplatin combined treatment is abolished upon p21
silencing.
Conclusions/Significance: Piroxicam/cisplatin combined treatment determines an apoptosis increase in MM cells, which is
dependent on the p21 expression. The results provided suggest that piroxicam/cisplatin combination might be tested in
clinical settings in tumor specimens that express p21.
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Introduction
Malignant mesothelioma (MM) is a rare, highly aggressive
tumor, accounting for less than 1% of all cancer deaths in the
world [1], that arises from the surface of serosal cells of the pleura,
peritoneum, and pericardium. The association between exposure
to asbestos and MM development is commonly accepted.
Epidemiological data indicate that in the next 30 years this
disease will cause a quarter of a million of deaths in Europe in
individuals exposed to asbestos [2]. The prognosis is generally
poor, with a reported median survival from presentation ranging
from 9 to 12 months in either untreated or treated patients [3].
Treatment of MM patients has included supportive therapy,
surgery, chemotherapy and radiotherapy [4]. Overall, clinical
benefits of conventional therapies are marginal, with chemother-
apy as the choice treatment, taking into account that surgery and
radiotherapy have limited benefits in highly selected patients -
reaching a median survival of approximately 1 year. To date no
chemotherapy regimen for MM has proven to be curative, and
new therapies for MM treatment are being developed testing
different drug combinations, that might be used as new therapies,
or as part of new combined multi-modality treatments, with
sequential surgery and/or radiotherapy.
The advent of genome-wide analyses that greatly enhanced the
comprehension of the molecular changes, cancer-type distinctive,
has allowed to shift cancer therapies from broad-spectrum
treatments towards cancer-specific and molecular-targeted treat-
ments, showing efficacy and a limited toxicity to normal cells.
Furthermore, analysis of the pathways specifically de-regulated in
cancer, have led to develop specific tumor inhibitors, as the
farnesyltransferase inhibitor [5], the anti-VEGF (vascular endo-
thelial growth factor) antibody bevacizumab [6], or the protea-
some inhibitor bortezomib [7]. Similar drugs have been tested also
in MM, as well as in the pre-clinical study based on cisplatin and
bortezomib, reporting enhanced apoptosis and increased cisplatin
cytotoxicity [8]. Among the combined chemotherapy regimens for
MM, two proved to be favourable to palliation: pemetrexed plus
cisplatin [9] and gemcitabine plus cisplatin [10].
A different combined treatment recently described by our group
in MM used the non steroidal anti-inflammatory drugs (NSAIDs)
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e23569piroxicam combined to cisplatin. This drug combination showed
an anti-tumor effect, with increasing survival both in vitro and in
vivo, as demonstrated in a murine orthotopic model of MM [11].
NSAIDs are commonly used as anti-inflammatory and analgesic
drugs. They are non selective inhibitors of both cyclooxygenase-1
(COX-1), an enzyme constitutively expressed in many tissues, and
cyclooxygenase-2 (COX-2), that is expressed at very low levels in
most tissues [12]. COX-2 can be induced by cytokines and stress
in various tissues and it is overexpressed in many cancers. The first
studies associating NSAIDs treatment with a reduced cancer risk,
were performed on colon cancer [13]. Since then, the antineo-
plastic effects of NSAIDs have been evaluated in many
randomized clinical trials [14] [15] and on several in vitro and in
vivo experimental MM models. In particular, NS398 produced a
significant reduction of proliferation level in MM cell lines, [16]
while celecoxib resulted efficient in inhibiting mesothelioma cell
growth [17].
In a previous work we have demonstrated a significant anti-
proliferative effect of piroxicam (P) in two mesothelioma cell lines
not expressing COX-2, MSTO-211H and NCI-H2452, treating
them with piroxicam alone or in combination with cisplatin (C).
Drugs combination resulted in a synergistic effect, suggesting that
piroxicam might sensitize MM cells to cisplatin cytotoxicity acting
via a COX-independent mechanism. The results were confirmed
in vivo, in a mouse MM model indicating that piroxicam and
cisplatin association specifically acts on cell cycle regulation
triggering apoptosis, and may hold promise in the treatment of
MM [11]. Finally in spontaneous MM in pets, we recently have
been able to show that piroxicam/cisplatin combination has
remarkable efficacy at controlling the malignant effusion second-
ary to MM in our samples [18].
Starting from this background, the goal of this work was to
dissect, at a molecular level, the effects of this combined treatment.
Molecular changes responsible for the anti-tumor effect following
the combined treatment were initially investigated by whole
genome transcription profling. Specifically, we used Affymetrix
microarray technology to identify differentially expressed genes in
MSTO-211H cell lines after the piroxicam/cisplatin combined
treatment. We associated apoptosis activation of the combined
treatment to p21 expression, since apoptosis enhancement is
impared upon silencing of p21. These results suggest a novel
mechanism for this drug combination that might be tested also in
other human cancers.
Results
Piroxicam and cisplatin combined treatment induces
apoptosis in MSTO-211H cells
Previous studies from our laboratory established a role in
mediating cell proliferation for the piroxicam/cisplatin combined
treatment. We showed that piroxicam acts on MM cells reducing
proliferation levels in a dose-dependent manner. Furthermore, as
revealed by our group, in a MM ortothopic model, mice treated
with combined therapy showed a prolonged survival and a tumor
growth reduction. We assumed that piroxicam could exert its
effects via COX-independent mechanisms because MSTO-211H
cells express at very low levels COX-2 proteins [11].
To further elucidate the effect of combined treatment on cell
cycle regulation and the downstream signalling, we exposed
MSTO-211H cells to both cisplatin and piroxicam/cisplatin in a
time course experiment, using the drug concentration able to
reduce cell proliferation by 50%, as we have previously showed
[11]. Apoptosis was investigated by means of DNA distribution in
flow cytometry analysis, using untreated cells as control. After
single cisplatin treatment, we detected a 14% of apoptotic
induction, while the comparison of cell DNA content between
piroxicam/cisplatin and untreated cells, revealed a 33% of
apoptosis increase after 24 hours treatment compared to control
(Figure 1A). This analysis revealed no apoptotic induction at
8 hours both in single or in combined treatment (data not shown).
These results were confirmed measuring the cell viability using the
trypan blue method (Figure 1B). Apoptosis was further evaluated
with Annexin V-FITC/PI staining confirming that combined
treatment induced up to 37% apoptosis increase compared to
control (Figure 1C).
To analyze if the effect exerted by piroxicam and cisplatin could
be viewed as a general characteristic of MM cells, we analyzed
apoptosis induction following the combined drug treatment in
other MM cell lines. In particular NCI, Mes1 and Mes2 were
treated as described above, then apoptosis was evaluated with
AnnexinV-FITC/PI. NCI and Mes1 cell lines showed a similar
apoptotic increase after combined treatment (Figure 2). We were
unable to detect any significant apoptotic event in Mes2 cells upon
single or combined treatment (data not shown).
Genome-wide profiling analysis leads to identify genes
involved in apoptosis enhancement following combined
treatment
In order to analyze, at a molecular level, the effect of the
combined treatment, and to identify the relative pattern modifi-
cations, we performed a transcriptional profiling on HGU133A
arrays, using MSTO-211H cells treated with piroxicam, cisplatin
or with piroxicam and cisplatin. Differential expressed genes in
treated cells were detected comparing their expression respect to
untreated cells.
On the basis of the above reported apoptotic induction, drug
treatments were done at times in which apoptosis induction was
undetectable (8 h) or present (24 h). Biological triplicates were
generated for each prototypic situation and data were analyzed
using the oneChannelGUI Bioconductor package [19].
The complexity of the data set was reduced removing the non-
significant probe sets, resulting in a total of 4,247 out of the 22,283
probe sets present in the microarray. To assess differential
expression, we used an empirical Bayes method [20] together
with a false discovery rate correction of the P-value [21].
Specifically, genes were selected using a corrected p-value#0.05
and |log2(fc)|$1. We detected a total of 536 differentially
expressed probe sets (Table S1).
To analyze in detail deregulated genes, and to identify a direct
correlation to apoptosis induction, we performed a functional
analysis using ‘‘Ingenuity Pathways Analysis’’ (IPA7.0, Ingenuity
SystemH). As shown in Figure 3, we observed a consistent number
of differentially expressed genes only after 24 h treatments both in
piroxicam and in piroxicam/cisplatin. We were unable to detect
differentially expressed genes upon cisplatin treatment, thus
supporting the hypothesis that the cisplatin-induced cytotoxicity
might be enhanced by piroxicam through the modulation of
specific endogenous effectors as for the previously described HtrA1
– a serine protease that acts as a tumor suppressor-like protein
[22]. Genes deregulated in the combined treatment were further
analyzed in IPA for their molecular and cellular function and
functional network. The analysis identified Cancer, Cell Cycle and
Cellular Growth and Proliferation as the top three categories among the
known affected biological function (Table 1) and Cell cycle, Cellular
movement and Cancer as the most representative functional network.
To find out the mechanism underlying the enhanced apoptosis
sensitivity in the combined treatment, we then focused our
attention to genes associated to the above mentioned functional
Apotosis Induction in Piroxicam/CDDP Treatment
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them with an opposite fold change in the single piroxicam
treatment (see Table S1). Among them, we found CDKN1A (p21)
one of the few genes up-regulated in this network (Table 2).
To better analyze the p21 function we used IPA to find
functional relationship with other genes involved in cell cycle
progression that could account for the apoptosis increase detected
in the combined treatment. As shown in Figure 4B, p21 is
Figure 1. Piroxicam and cisplatin combined treatment induces apoptosis. A, MSTO-211H cells were exposed to cisplatin or to piroxicam and
cisplatin and DNA content was analyzed by flow cytometry analysis. After 24 hours untreated (Ctrl) and treated cells (C, P/C) were collected, labeled
with propidium iodide (PI) and analyzed. B, Cell viability analysis with the trypan blue. C, Apoptosis analysis by Annexin V-FITC/PI (Q1: necrosis; Q2:
late apoptosis; Q3: healthy cells; Q4: early apoptosis). D, data summary of the apototic index. Data were performed on three independent
experiments with comparable results. Ctrl: cells, C: cisplatin, P/C: piroxicam and cisplatin.
doi:10.1371/journal.pone.0023569.g001
Figure 2. Apoptosis induction after combined treatment in MM cell lines. A and B, Apoptosis analysis by Annexin V-FITC/PI in NCI (A) and
Mes1 (B) (Q1: necrosis; Q2: late apoptosis; Q3: healthy cells; Q4: early apoptosis). C and D, data summary of the apototic index. Cells were treated as
described above for the MSTO-211H. Data were performed on three independent experiments with comparable results. Ctrl: cells, C: cisplatin, P/C:
piroxicam and cisplatin.
doi:10.1371/journal.pone.0023569.g002
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combined treatment.
Microarray results were confirmed by quantitative real-time
reverse-transcription polymerase chain reaction (qRT-PCR). The
analysis was performed on MSTO-211H cells for all the genes
depicted in Figure 4 both after single piroxicam or combined
piroxicam/cisplatin treatment. We also tested their expression, on
samples previously described by our group [23], where microarray
analysis was used to compare human MM samples with respect
normal pleura to detect MM associated genes. As reported in
Table 3, qRT-PCR data were in good agreement to the
microarray results, as the array expression values were confirmed
for almost all genes either in cells or in human samples. The results
obtained were in agreement with other published works (Table 3)
and they also reinforced the idea that p21 might be an important
effector of the combined treatment.
p21 protein profiling following combined treatment
p21 was initially identified as a p53-target gene, a tumor
suppressor activated in response to DNA damage [24]. Because
our microarray analyses did not detect any transcription
deregulation of p53 expression, we wondered if we could detect,
between single and combined treatments, a p53 differential
expression at protein level. We performed a Western blot analysis
in MSTO-211H using total protein extracts. As shown in
Figure 5A, we detected an increase of p53 levels in cisplatin
treatment, probably related to the cisplatin-induced cellular stress
that acts through nuclear DNA binding [25], as well as in
piroxicam/cisplatin treatment. Western blot analyses could not
detect p21 protein increase and, in agreement with previously
reported data [26] we noticed a decrease in the P/C treatment
(Figure 5A).
To refine our knowledge on p21 expression at protein level we
also investigated its subcellular localization. We analyzed protein
expression either in cytoplasm or in nuclear extracts. As shown in
Figure 5B, an increase in nuclear localization for p53 was found, as
a consequence of cisplatin-induced cellular stress [25]. We also
observed a similar effect for p21 which was mainly localized in the
nucleus. Furthermore, we observed that p21 nucleus/cytoplasm
ratio increased to a greater extent when we prolonged the
piroxicam treatment for additional 24 hours before adding
cisplatin (Figure 5B, lanes P24h) p21 nuclei shifting in the P/C
combined treatment well agree with the observed apoptosis
Figure 3. Differentially expressed genes enriched after single
or combined treatment. Gene numbers after different time and drug
treatments are shown. It is evident that only a 24 hour treatment
reveals a consistent number of genes both in single piroxicam
treatment and in the combined one. C: cisplatin; P: piroxicam; P/C:
piroxicam and cisplatin.
doi:10.1371/journal.pone.0023569.g003
Table 1. Top molecular and cellular functions at 24 hours
piroxicam/cisplatin treatment.
Name P- value Molecules
Cancer 1.15E-13–9.71E-03 143
Cell cycle 4.14E-13–9.53E-03 125
Cellular growth and proliferation 4.28E-10–9.71E-03 94
Cellular movement 4.74E-09–8.96E-03 28
Cell death 5.61E-08–9.71E-03 146
doi:10.1371/journal.pone.0023569.t001
Table 2. Genes associated to Cell Cycle, Cellular Movement,
Cancer Functional Network.
Associated Genes Fold change
ASPM 21.4
BCCIP 22.04
BIRC5 21.39
BUB1 21.36
BUB1B 2.48
CCNA2 22.71
CCNB1 21.17
CCNB2 21.07
CDC2 21.20
CDCA3 21.29
CDK2 21.01
CDKN1A 3.32
CDKN3 21.27
CEP55 21.08
DDB2 21.5
DLG7 21.23
ECT2 21.35
FEN1 1.89
FOXM1 21.54
KIF14 22.73
KIF20A 1.08
KIF23 21.43
KIF4A 1.02
LGALS3BP 21.72
MCM4 1.17
NCAPD3 1.20
NDC80 21.07
PBK 21.24
PHGDH 21.76
PRC1 21.17
RACGAP1 21.2
TTK 22.09
doi:10.1371/journal.pone.0023569.t002
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p21 [27]. It has been reported that p21 can regulate cell cycle
progression through inactivation of the cyclin-dependent kinase
(Cdk)/cyclin complexes that are localized in the nucleus when
active, and that the enhancement of p21 is linked to reduced
expression of CDK and to cell growth inhibition. Despite this p21
inhibitory function, the inhibition of CDK activity determines the
inactivation of the retinoblastoma tumor suppressor protein (pRB)
that in turn sequesters E2F1 (E2 Family Member 1), thus leading
to apoptosis induction [28].
p21 silencing prevents apoptosis after piroxicam/
cisplatin combined treatment
Before performing further investigation on p21 we sequenced in
MSTO-211H cells all p21 coding exons, confirming the absence of
any mutation. To gain insight the functional role of p21 in
apoptosis observed after the P/C combined treatment, we silenced
p21 expression by means of small interfering RNA technology
(siRNA) and analyzed the effects on the cell viability after drug
treatments.
Silencing was confirmed analyzing p21 protein levels. As shown
in Figure 6, the protein was completely absent in p21 siRNA-
transfected cells both at 24 or 48 hours after transfection, even in
presence of drug treatments (Figure 6B).
To analyze the p21 silencing effects on cell cycle, we measured
the DNA content by flow cytometry analysis after silencing.
Analyses were carried out on cells exposed to cisplatin or to
piroxicam/cisplatin 24 hours after transfection. Figure 7 shows
that upon p21 silencing, cisplatin single treatment induced
apoptosis activation comparable with untreated cells, while we
Figure 4. IPA functional pathway analysis. p21 functional relationship with other differentially expressed genes involved in cell cycle
progression detected in this work. A, Expression after 24 hours treatments with piroxicam. B, Expression after 24 hours treatments with piroxicam/
cisplatin. For each gene the relationship and the expression (red up-regulated, green down-regulated) are shown. Arrows indicate the direction of the
relationship.
doi:10.1371/journal.pone.0023569.g004
Table 3. Validation of Array-Based Gene Expression Profile by Real-Time PCR in MM cell after P or P/C treatment and in human MM
samples.
MSTO11H
a) Mesothelioma
b)
Gene name Fold Change
Real time
validation Fold Change
Real time
validation
Association to
Mesothelioma
PP / C
BIRC5 1.50 21.39 Yes 3.59 Yes [47], [48], [49]
BUB1B - 21.36 No 3.88 No
CCNB1 - 21.17 Yes 3.44 Yes [47], [50]
CDKN1A - 3.32 Yes 20.61 Yes [51]
CDKN3 - 21.27 Yes 2.44 Yes
DLG7 1.27 21.23 Yes 3.89 Yes
FOXM1 - 21.54 Yes - - [50]
LGALS3BP - 21.72 Yes 0.74 Yes
MAD2L1 1.53 - No 3.55 Yes
RACGAP 1.01 21.22 No 2.12 No
a)after 24 hours treatment.
b)human sample [18].
doi:10.1371/journal.pone.0023569.t003
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cells in combined treatment (Figure 7A). Apoptosis was instead
unaffected using a control siRNA (Figure 7B). These results were
confirmed measuring the cell viability using the trypan blue
method (Figure 7 C, D).
The above mentioned observations, demonstrate a tight
relationship between p21 and apoptosis. If we also take in account
that, under the same conditions, p53 protein level is not affected
(Figure 6B), we can conclude that apoptosis induced by the
combined treatment is mediated by p21 in p53 – independent way.
In this view we have verified the presence of a direct correlation
amongp21silencing and some ofitsdownstream geneslinkedtocell
cycle effects (Table 3), also detected by the microarray analysis.
Microarray analyses revealed that the majority of transcription
changes was detected after 24 hours treatment with piroxicam or
with piroxicam/cisplatin and that the functional classes most
affected by these changes are associated to cancer, cell cycle,
cellular growth and proliferation. Specifically we observed that
p21-related genes are all down-regulated in combined treatment,
and that they are also characterized by opposite expression trend
when compared to piroxicam alone (Table S1).
These genes have a role in cell growth and mitosis and they are
essential for mitotic progression. Furthermore, most of them are
considered cancer therapeutic targets.
Specifically, BIRC5, a member of the inhibitor of apoptosis
(IAP) gene family, has been shown to inhibit apoptosis and
enhance proliferation [29]. BIRC5 is up-regulated in almost all
human tumors and its functional involvement, in apoptosis as well
as in proliferation, leads to consider it as a new target for cancer
treatment [30].
Furthermore, BUB1 and MAD2L1 are required for spindle
checkpoint functions and for right metaphase chromosomal
Figure 5. p21 protein is differently expressed in sub- cellular compartment. A, Western blot analysis and relative expression level on p53
and p21 proteins after 24 hours P, C or P/C treatment in MSTO11H. The analysis reveals an increase of p53 levels after C treatment probably related to
the cisplatin-induced cellular stress. Indeed p21 levels appear decreased in the P/C combined treatment. Total proteins were incubated with p21
antibody, or p53 antibody. B, Western blot analysis and relative expression level on p53 and p21 proteins in cytoplasmic and nuclear subcellular
fractions. Most of the p53 protein is localized in the nucleus and there is a similar result for p21. In addition the p21 nucleus/cytoplasm ratio increases
in the prolonged piroxicam pre-treatment before adding cisplatin (lanes P24h). Proteins were probed with specific cytoplasmic (tubulin) or nuclear
(RCC1) antibodies to exclude fractions cross-contamination. In all the experiments, actin was used as loading control. Histograms of relative
expression level refer to p53 and p21 normalized expression and derived by the analysis of three independent experiments. Statistical analysis was
done as indicated in Material and Methods. -: untreated cells, P: piroxicam; C: cisplatin; P/C: piroxicam and cisplatin P24h: piroxicam and cisplatin after
piroxicam pretreatment.
doi:10.1371/journal.pone.0023569.g005
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checkpoints at the centromere and it is involved in tumor cell
proliferation because its suppression determines apoptotic cell
death. MAD2L1 in association with the cyclin B-ubiquitin ligase, is
part of the anaphase-promoting complex, controlling the meta-
phase-anaphase transition. Depletion of these mitotic control
proteins is associated to premature senescence and this phenotype
is triggered by p21 [32].
Galectin-3-binding protein (LGALS3BP) – belongs to a
protein family with high affinity for beta-galactoside and it is
expressed in many tumor cells being associated to carcinogenesis.
Interestingly, breast carcinoma cells overexpressing LGALS3BP,
show apoptosis resistance in response to anticancer treatment
[33].
We also found down-regulated two genes involved in citokinesis:
RACGAP1 and DLG7. RACGAP1 is a Rho GTPase that forms
the central spindlin complex, a complex essential for the assembly
of a microtubule structure and for the subsequent formation of the
contractile ring that, in turn, drives cytokinesis [34]. DLG7 is an
essential component of the mitotic apparatus required for the
assembly of the bipolar spindle that has oncogenic activity because
it promotes cell survival. DLG7 is tightly regulated along the cell
cycle - with increasing transcription levels from G1/S to G2/M -
and its depletion determines chromosome congression delay [35].
It has been described as overexpressed in human hepatocarcinoma
[36] and MM [23].
FOXM1 is instead a transcription factor required for mitosis
progression whose loss determines spindle defects and centrosome
amplification [37]. According to previously reported data, we
found FOXM1 down-regulation linked to reduced expression of
two direct transcriptional targets: CCNB1 - a key regulator of the
G2/M checkpoint of the cell cycle, and CDKN3 - a gene required
for the G1/S progression, whose expression results down-regulated
in absence of FOXM1 [38].
Particularly interesting are the results obtained on CDKN3.
CDKN3 expression is completely modified upon p21 silencing,
resulting in an up-regulation both at RNA and protein levels
(Figure S1). It was recently shown that CDKN3 expression is
inversely correlated to p21 induction and that CDKN3 down-
regulation negatively affects cell growth [39].
Discussion
Evasion from apoptosis is one of the fundamental hallmarks of
cancer, and apoptosis resistance is one of the major mechanisms
related to drug resistance in tumour cells. Recent studies have showed
that combined therapies acting on cell cycle - through pro-apoptotic
proteins or specific miRNA - enhance tumor sensitivity to drugs [40].
Figure 6. Effects of p21silencing on protein expression. A, Western blot analysis and relative expression level on p21 expression after p21
siRNA transient experiment. MSTO cells transfected with control or p21 siRNA were harvested at 24 or 48 hours after transfection. Total proteins were
incubated with p21 antibody, or p42 antibody as internal control. Complete silencing was detected both at 24 and 48 hours. B, Western blot analysis
and relative expression level on p53 expression after 24 hours, C or P/C combined treatment of MSTO-211H p21 silenced cells. 24 hours after
silencing, cells were exposed to different drugs as indicated before protein extraction. Total proteins were incubated with p21 antibody, or p53
antibody. In all the experiments, actin was used as loading control. Histograms of relative expression level refer to p53 and p21 normalized expression
and derived by the analysis of three independent experiments. Statistical analysis was done as indicated in Material and Methods. Cells: untreated
cells; Ctrl: cells transfected with control siRNA; C: cisplatin; P/C: piroxicam and cisplatin.
doi:10.1371/journal.pone.0023569.g006
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exertsanapoptoticeffectonMMcells.Genome-widetranscriptome
analyses led us to identify p21 as the possible apoptosis mediator
acting as downstream target of the piroxicam/cisplatin treatment.
p21 belongs to the CDK (cycline-dependent kinase) family
inhibitors that act on kinase activity of the CDK-cyclin complexes.
p21 acts as a regulator of cell cycle progression at G1, inhibiting
the activity of cyclin-CDK2 or -CDK4 complexes required for
G1/S transition [41].
As a proliferation inhibitor, p21 plays an important role in
preventing tumor development. Ectopic overexpression of p21
leads to cell growth arrest in G1 and G2 and this arrest is
accompanied by phenotypic markers of senescence in the cell [32].
p21 promotes apoptosis through repression of different genes
involved in cell cycle progression. Microarray data and qPCR
provided the basis for the hypothesis that p21 plays a key role in
piroxicam functionality in the view of a sensitization of the cells to
cisplatin treatment. However the presence of discrepancy between
transcription and translation level of p21 in the combined
treatment highlighted the need of further investigations to
understand the role of p21.
Specifically the presence of differential expression at transcrip-
tional level of p21 upon the P/C combined treatment prompted us
to hypothesize a role of p21 in the effects induced by the combined
treatment. Although silencing of p21 impairs the functionality of the
P/C combined treatment, reinforcing the idea of an involvement of
p21 in the mechanism of action of P/C treatment, p21 transcription
changes are not translated at protein level. However, we have
observed that p21 localization changes upon the combined
treatment, resulting in a nuclear accumulation of p21.
Recent studies provide evidences on the functional role of p21
in function of its cellular localization. Specifically it has been
shown that p21 in its nuclear localization is associated to anti-
proliferative functions as instead p21 cytoplasmic localization is
linked to cell cycle progression and to anti-apoptotic functions
[27].
Therefore, the increase in nuclei localization of p21 observed
here upon the P/C combined treatment (Figure 5B) well agree
with the above mentioned published data and provide new incite
on the mechanism of action of the P/C combined treatment.
Interestingly, we have also observed in MM patients a
significant positive relationship between p21 transcription expres-
sion level and their overall survival [42]. Therefore, determination
of p21 expression might bear a prognostic significance in patients
affected with MM.
In conclusion, the results shown here in combination with our
previous data [11], lead us to suggest that piroxicam/cisplatin
treatment of MSTO-211H cell line determines in vivo a tumor
regression and a survival increase which is dependent by p21.
Materials and Methods
Cell lines and reagents
The human mesothelioma cell lines MSTO-211H, NCI-H2452
(NCI), IST-Mes1 (Mes1) and IST-Mes2 (Mes2) were obtained
from the American Type Culture Collection (Rockville, MD,
USA). IST-Mes1 (Mes1) and IST-Mes2 (Mes2) were obtained
from the ISTGE (Istituto Nazionale per la Ricerca sul Cancro –
Genova). Piroxicam (Pfizer, New York, NY) was a 60-mmol/L
injectable solution; cisplatin (Pharmacia-Italia, MI, Italy) was a
50 mmol/L injectable solution. Cells were cultured as monolayers
in flasks using American Type Culture Collection complete growth
medium in a humidified atmosphere containing 5% CO2 at 37uC.
For drug treatments, cells were seeded in complete growth media
Figure 7. Apoptosis decrease in p21 silenced cells after piroxicam/cisplatin treatment. MSTO-211H cells were exposed to cisplatin or to
piroxicam and cisplatin after 24 hours transfection with p21 siRNA or with the control siRNA. After transfection cells were drug-treated for additional
24 hours, then DNA content was analyzed by flow cytometry analysis with propidium iodide staining treating cells. A, p21 silenced cells show a
marked apoptosis reduction after the combined treatment. B, Apoptosis was completely restored in the same experiments using control siRNA. C and
D, Cell viability analysis with the trypan blue showed a reduced apoptosis only in p21 silenced cells. Data were performed on three independent
experiments with comparable results. Ctrl: cells, C:cisplatin, P/C: piroxicam and cisplatin.
doi:10.1371/journal.pone.0023569.g007
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not cell-doubling. Then, cells were treated with piroxicam
(760 mM) and cisplatin (4.5 mg/mL) alone or in combination for
8, 24 and 48 hours. Where indicated, i.e. P24h, cells were
pretreated with piroxicam for 24 hours before adding cisplatin.
Controls samples were untreated.
Cell cycle and cell viability analysis
Unsynchronized MSTO cells (10
6) were treated with piroxicam
and cisplatin alone or in combination, as described in the previous
section. Cells were harvested and stained with either propidium
iodide or trypan blue. Cells stained with propidium iodide (PI)
were subjected to FACS analysis, after incubation for 4 hours at
4uC in hypotonic PI solution (50 mg/ml PI, 0.1% sodium citrate,
0.1% Triton X-100, and 20 mg/ml DNase-free RNase A) then
analyzed on a FACScan flow cytometer (Becton Dickinson, San
Jose, CA). Histograms of cell number versus logarithm integrated
FL3 fluorescence were recorded for 20.000 nuclei at flow rates no
greater than 50 to 100 events per second. Cells with subdiploid
DNA content (sub-G0/G1 peak) were considered apoptotic cells.
Cell viability was also analyzed using the trypan blue dye exclusion
method. For apoptosis analysis, harvested cells were stained with
Annexin V-FITC and propidium iodide according to the
manufacturer’s instruction (Miltenyi Biotec, Germany) and then
subjected to the same analyzer. All the experiments were
performed in triplicate. Data are expressed as the mean 6SD.
GeneChip array sample preparation
Total RNA was extracted and purified using the RNeasy Midi
kit (Qiagen, Valencia, CA). Biotinylated cRNA target preparation
and target hybridization to HGU133A arrays, containing 22,000
probe sets for human transcripts, were performed according to
Affymetrix (Santa Clara, CA) instructions. All the hybridization,
washing, staining and scanning procedures were done using a
Genechip Affymetrix station (FS 450, Scanner 3000) as recom-
mended by manufacturer. The CEL file produced by microarray
scanning were used for the subsequent statistical analysis.
GeneChip array data analysis
Four prototypic situations were analyzed to generate back-
ground-normalized image data: untreated cell line, single
piroxicam or cisplatin treated cell line, piroxicam plus cisplatin
treated cell line. Array analyses were carried out in triplicates for
each condition. Microarray quality control and statistical valida-
tion were performed using oneChannelGUI Bioconductor pack-
age (http://www.bioconductor.org/packages/2.1/bioc/html/one
ChannelGUI.html) a graphical interface used to run the analysis
described below [19].
The presence of hybridization/construction artifacts was
evaluated with the fitPLM function. This application allowed us
to eliminate from the subsequent analysis six CEL files showing an
outlier raw intensity box plot.
After probe (PM) intensity distribution evaluation, probe set
intensities were obtained with GCRMA [43]. The number of
genes evaluated was reduced by applying an interquartile (IQR)
filter (7625 probe sets with IQR$0.25 were retained from 22283
starting probes) followed by an intensity filter (4247 probe sets with
expression signal $100 in at least 25% of the arrays were retained)
to remove the non significant probe sets (i.e. those not expressed
and those not changing) [44]. To assess differential expression
between single and combined treatments, we used linear model
analysis. Differential gene expression was detected using an
empirical Bayes method [20] together with a false discovery rate
correction of the P-value [21]. Specifically we checked differential
expression in the following comparisons: piroxicam vs. control
8 hours, cisplatin vs. control 8 hours, piroxicam plus cisplatin vs.
control 8 hours, piroxicam vs. control 24 hours, cisplatin vs.
control 24 hours, piroxicam plus cisplatin vs. control 24 hours.
Differentially expressed genes were selected using a corrected p-
value threshold of 0.05 and fold change threshold of |log2(fc)|$1.
Ingenuity Pathway Analysis (IPA, http://www.Ingenuity.com)
was used to functionally annotate genes according to biological
processes and canonical pathways.
Microarrays data reported in the manuscript were described in
accordance with MIAME guidelines. Microarray data were
deposited on GEO database as GSE22445 series (http://www.
ncbi.nlm.nih.gov/projects/geo/).
Quantitative Real-Time PCR analysis
Total RNA (2 mg) from each sample was converted to cDNA
using High- Capacity cDNA Reverse transcription kit (Applied
Biosystem, Foster City, CA) under conditions described by the
supplier. Gene specific primers for the selected genes (BIRC5:
Forward 59 GGATCACGAGAGAGGAACATAA, Reverse 59
TCCGCAGTTTCCTCAAATTCTT; BUB1B: Forward 59 TC-
AATTGGGTTCTAAGCTGGTCTA, Reverse 59 TCGTACA-
CCTGGGCAAAGG; CCNB1: Forward: 59GATCGGTTCATG-
CAGAATAATTGT 39, Reverse 59 CATGGCAGTGACAC-
CAACCA 39; CDKN1A: Forward 59 CATGACAGATTTCTAC-
CACTCCAAA, Reverse 59 RTCCTGTGGGCGGATTAGGT;
CDKN3: Forward: 59 GGCAATACAGACCATCAAGCAA 39,
Reverse 59 TGATGATAGATGTGCAGCTAATTTGT 39;
DLG7: Forward 59 CGGTCCTCAGAATACGAAAAGTG, Re-
verse 59 TCTATGCTGCTCCTGCTTTCAG; FOXM1: For-
ward: 59 TGCCCGAGCACTTGGAAT 39, Reverse 59 CGG-
CGGAGCTCTGGATT 39; LGALS3BP: Forward 59 CCTTC-
GGGCAAGGATCAGGCCCCATCATG 39, Reverse 59 ACTT-
GCAGTCGGCCAGTGA 39; MAD2L1: Forward 59 GGGAGC-
GCCGAAATCG 39, Reverse: 59 CACGCTGATATAAAATGC-
TGTTGA 39; RACGAP: Forward, 59 TCCTCATGATTCACT-
TGCAGAGA 39, Reverse 59 CCAGATTGGCAACATCCATT-
T3 9) were designed using Primer Express 2.0 software (Applied
Biosystem). GAPDH was used as internal control. Quantitative
PCRs were done on an ABI PRISM 7900HT Sequence Detection
System (Applied Biosystems). The entire procedure for qRT-PCR
analysis - primer design, reactions, amplicon specificity and
determination of gene target expression levels - was performed
as previously described [23].
Relative gene expressions were calculated by relative quantifi-
cation approach [45], using control samples as calibrator. Target
genes were accepted as differential expressed when was DDCt
|.1| - corresponding to 2-fold change in transcript abundance.
The standard deviation was calculated for samples within each
group.
p21 sequence analysis
Primers were designed on the basis of the Ensembl Genome
database sequence for Human CDKN1A. A total of 2 pairs of
primers covering the two coding exons, including intron/exon
junctions, were used: p21up1 Forward: 59 CTGAGGTGACA-
CAGCAAAGC 39, Reverse: 59 CAGGACCAGACAGGTCAGC
39; p21up2 Forward: 59 CCCAGGGAAGGGTGTCCT 39,
Reverse: 59 CGGGAGAGAGGAAAAGGAGA 39.
Genomic DNA from MSTO-211H cells was isolated as
described by Sambrook and Russel [46]. The PCR-amplified
sequences were aligned using the EMBOSS Pairwise Align-
ment Algorithms (http://www.ebi.ac.uk/Tools/emboss/align/).
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sequence from the Ensembl database (www.ensembl.org).
Transient siRNA
Transient siRNA transfections were performed with SignalSi-
lence p21 Waf1/Cip1 siRNA Kit (Cell Signaling Technology,
Danvers, MA), according to the manufacturer’s instructions with
50 nM p21 siRNA or control siRNA and Interferin (Polyplus-
transfection, New York, NY) as transfection reagent. For each
sample 100,000 cells/ml were plated in complete medium
containing 10% FCS a day before transfection. 24 hours after
transfection drug treatments were done for additional 24 hours.
Protein extraction and Western blot analysis
Proteins gel electrophoresis, transfer and visualization were
performed using standard techniques. Briefly, MSTO cells were
lysed at 4uC for 1 hour in RIPA lysis buffer (150 mM NaCl,
1%NP-40, 50 mM Tris pH 8.0, 0.5% Na-deoxycholate, 0.1%
SDS) supplemented with a protease inhibitor cocktail (Sigma-
Aldrich, St. Louis, MO), followed by centrifugation at 14,000 g for
159 at 4uC to separate cell debris from protein. Cytoplasmic and
nuclear extracts were prepared using a nuclear extract kit (Active
Motif, Carlsbad, CA) following the manufacturer’s instructions.
Proteins (60 mg) were resolved on 10% SDS-PAGE gels,
transferred to nitrocellulose membrane and incubated overnight
at 4uC with p21, p53, CDKN3 or actin (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA) monoclonal antibodies. Cross contamina-
tion of nuclear and cytoplasmic fractions was excluded using
RCC1 (Santa Cruz) or alpha tubulin (Abcam, Cambridge, UK)
antibodies respectively. Actin was used to normalize the sample
loading. Proteins were visualized with peroxidase-conjugated
protein A (200 ng/ml), and ECL Plus detection reagents
(Amersham, GE Healthcare Bio-Sciences Corp., Piscataway, NJ).
Electrophoretic band quantification was performed using
ImageJ software (http://rsbweb.nih.gov/ij/). Statistical analysis
was performed using GraphPad Prism 5.0H statistical software
(GraphPad Software Inc., La Jolla, CA). Paired t test was used for
comparison of two paired groups. Multiple comparisons were
performed by the repeated measures ANOVA test with the
Bonferroni correction for multiple.
Supporting Information
Figure S1 CDKN3 expression is associated to p21.
mRNA and protein levels were measured after p21 silencing. A,
Real-Time PCR analysis of CDKN3 in MSTO-211H cells shows
an increased expression in absence of p21. B, Western blot analysis
and relative expression level of CDKN3 protein levels after p21
siRNA transient experiments. Cells transfected with control (-) or
p21 siRNA were harvested at 24 hours after transfection. Total
proteins were incubated with CDKN3 antibody or p21 antibody.
Actin was used as loading control. Histograms of relative
expression level refer to CDKN3 normalized expression and
derived by the analysis of three independent experiments.
Statistical analysis was done as indicated in Material and Methods.
(TIF)
Table S1 Differentially expressed probe sets after
24 hours with piroxicam or piroxicam/cisplatin treat-
ment.
(XLS)
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